Literature DB >> 11929317

The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.

Patrick J Marroum1, Jogarao Gobburu.   

Abstract

The product label, or package insert, is the 'manual' for the safe and effective use of a drug. Important pharmacokinetic and pharmacodynamic properties of a drug product should appear in the label under specific sections, as required in the Code of Federal Regulations (CFR), using a format and language recommended by the Food and Drug Administration (FDA) in various guidances to the industry. The relevant regulations and guidance documents impacting on how this information is conveyed to the healthcare professional are discussed, with special emphasis on how the new proposed rule will impact upon how information is to be conveyed. With the availability of new clinical pharmacology information not available at the time of approval, package inserts for older drugs should be updated to reflect the new data and recommend the proper dosage regimen, enabling prescribers to optimise drug therapy and minimise possible adverse events.

Mesh:

Year:  2002        PMID: 11929317     DOI: 10.2165/00003088-200241030-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  3 in total

1.  In vitro metabolic interaction studies: experience of the Food and Drug Administration.

Authors:  R Yuan; T Parmelee; J D Balian; R S Uppoor; F Ajayi; A Burnett; L J Lesko; P Marroum
Journal:  Clin Pharmacol Ther       Date:  1999-07       Impact factor: 6.875

2.  Assessment and reporting of clinical pharmacology information in drug labeling.

Authors:  D A Spyker; E D Harvey; B E Harvey; A M Harvey; B H Rumack; C C Peck; A J Atkinson; R L Woosley; D R Abernethy; L R Cantilena
Journal:  Clin Pharmacol Ther       Date:  2000-03       Impact factor: 6.875

3.  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Authors:  C C Peck; W H Barr; L Z Benet; J Collins; R E Desjardins; D E Furst; J G Harter; G Levy; T Ludden; J H Rodman
Journal:  Clin Pharmacol Ther       Date:  1992-04       Impact factor: 6.875

  3 in total
  5 in total

1.  Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change.

Authors:  Angelica P Herrera; Shedra Amy Snipes; Denae W King; Isabel Torres-Vigil; Daniel S Goldberg; Armin D Weinberg
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

2.  Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management?

Authors:  Meret Martin-Facklam; Jens Rengelshausen; Yorki Tayrouz; Nahal Ketabi-Kiyanvash; Heike Lindenmaier; Verena Schneider; Verena Bergk; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2004-12-14       Impact factor: 2.953

3.  Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature.

Authors:  Verena Bergk; Walter E Haefeli; Christiane Gasse; Hermann Brenner; Meret Martin-Facklam
Journal:  Eur J Clin Pharmacol       Date:  2005-06-28       Impact factor: 2.953

4.  Eplerenone: a new aldosterone receptor antagonist--are the FDAs restrictions appropriate?

Authors:  D A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

5.  Dynamic enhancement of drug product labels to support drug safety, efficacy, and effectiveness.

Authors:  Richard D Boyce; John R Horn; Oktie Hassanzadeh; Anita de Waard; Jodi Schneider; Joanne S Luciano; Majid Rastegar-Mojarad; Maria Liakata
Journal:  J Biomed Semantics       Date:  2013-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.